No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Gary Frashier?

Mr. Gary E. Frashier MBA PE

Managing Partner

Targeted Technology

HQ Phone: (210) 558-8896

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Targeted Technology

18618 Tuscany Stone Drive Suite 100

San Antonio, Texas 78258

United States

Company Description

About Targeted Technology: Targeted Technology is a San Antonio-based venture capital firm which focuses on early stage investments in companies that can advance ground breaking or disruptive technologies to significantly improve the practice of medicine ... more

Find other employees at this company (1,457)

Background Information

Employment History

Chairman and Chief Executive Officer

OSI Pharmaceuticals , Inc.

Executive Vice President

Millipore Corporation

President and Chief Executive Officer of Waters Chromatography Subsidiary

Water and Associates LLC

Strategic Partner

SV Life Sciences

President and Principal

Management & Associates Inc


Board Member
BioMed SA

Board Member
Metric Medical Devices Inc

Board Member
ViroXis Corporation

Santalis Corporation

Board Member
StemBioSys , Inc.

Board Member
Boston Life Sciences , Inc.

Member, Advisory Boards
Texas Tech University


Board Member
Achillion Pharmaceuticals , Inc.

Business Advisory Board Member
America Stem Cell , Inc.

Board Member
Inex Pharmaceuticals Corporation


Member, Advisory Boards
Massachusetts Institute of Technology

Young Presidents' Organization Inc



Chemical Engineering

Texas Tech


Chemical Engineering

Texas Tech University


Massachusetts Institute


Massachusetts Institute of Technology




Web References (103 Total References)

Targeted Technology | Jim Traa [cached]

Gary Frashier, MBA, PE

Targeted Technology | Gary Frashier [cached]

Gary Frashier, MBA, PE Targeted Technology | Gary Frashier Targeted Technology

Gary Frashier, MBA, PE
Gary Frashier
Managing Partner
Gary Frashier brings extensive experience to the Fund, having served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. Gary served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, "Tarceva", was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion.
Prior to OSI, Gary served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies.
Gary financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. Gary has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Gary has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).

Targeted Technology | Alan Dean [cached]

Gary Frashier, MBA, PE

With directors Robert Langer (MIT), Henry Brem (John's Hopkins) and Gary Frashier (OSI), Peter and his management team negotiated a Special Protocol Assessment with the US FDA that reduced Altropane's Phase 3 registration trial requirements by 6 years and $130 million while extending the company's intellectual property expiry from 2013 to 2028.

Leadership Items [cached]

Gary Frashier, M.B.A., P.E., Managing Partner

Targeted Technology (Venture Capital/Investors)

Achillion Pharmaceuticals: Board of Directors [cached]

Gary E. Frashier

Mr. Frashier joined Achillion's Board of Directors in March 2008 and currently serves as Chair of the Compensation Committee and as a member of the Audit Committee.

Similar Profiles

Other People with this Name

Other people with the name Frashier

Phyllis Frashier
Kegler , Brown , Hill & Ritter

Thomas Frashier
ihs markit ltd.

Karen Frashier
Advocate Marketing PR LLC

Mike Frashier
RIDES Mass Transit District

Rebecca Frashier
Metropolitan Life Insurance Company

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory